Integra Lifesciences (IART) Downgraded by BidaskClub to Strong Sell

Integra Lifesciences (NASDAQ:IART) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday, January 5th.

IART has been the topic of several other reports. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Tuesday, October 10th. UBS Group reissued a “buy” rating and issued a $57.00 target price on shares of Integra Lifesciences in a research report on Tuesday, October 31st. Jefferies Group reissued a “buy” rating and issued a $56.00 target price on shares of Integra Lifesciences in a research report on Sunday, October 29th. Wells Fargo & Co cut Integra Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Sunday, October 29th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $52.70.

Integra Lifesciences (NASDAQ IART) opened at $52.82 on Friday. The stock has a market capitalization of $4,197.76, a PE ratio of 29.55, a price-to-earnings-growth ratio of 1.71 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra Lifesciences has a 12-month low of $40.51 and a 12-month high of $56.42.

In other news, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 21.50% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC raised its stake in Integra Lifesciences by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its stake in Integra Lifesciences by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Integra Lifesciences by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares during the period. Whittier Trust Co. bought a new stake in Integra Lifesciences during the 3rd quarter valued at approximately $169,000. Finally, San Francisco Sentry Investment Group CA bought a new stake in Integra Lifesciences during the 2nd quarter valued at approximately $174,000. 87.63% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/31/integra-lifesciences-iart-downgraded-by-bidaskclub.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply